Lynch Lab for Novel Biomedical Optics



Subscribe to be notified of changes or updates to this page.

3 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

Interested candidates should reach out to

The Lynch Lab employs cutting-edge biomedical optical tools to better understand risk for neurologic injury in children with cardiac diseases. Our innovative approach revolves around noninvasive techniques for measuring cerebral oxygen delivery and utilization, ushering in a new era of neuromonitoring and improved neurologic outcomes.

Our research covers a wide range of areas, from studying the vulnerable period after birth when infants with critical congenital heart disease are awaiting their life-saving procedures to improving neurologic outcomes during neonatal cardiac surgeries. We're also investigating the neurologic impact of procedures like device closure of patent ductus arteriosus in premature babies, monitoring intracranial pressure in patients with Glenn physiology, and measuring tissue water content in patients with lymphatic abnormalities.

Our interdisciplinary approach sets our lab apart. Dr. Lynch's unique background in both physics and pediatric cardiac anesthesia brings together the worlds of science and medicine. Through close collaboration with other labs in the CHOP Biomedical Optics Group and researchers at the University of Pennsylvania, we combine cutting-edge technology with clinical experience to find practical solutions for better neuromonitoring and improved neurologic outcomes in children with heart conditions. Join us in our quest to make a real impact in pediatric cardiac care, one optical innovation at a time.

Research Highlights

  • Development and utilization of novel optical neuromonitoring tools for improved cerebral protection during cardiac surgery
  • Novel findings on the importance of timing of surgery in critical congenital heart disease on neurologic outcomes
  • New revelations on cerebral physiology during the vulnerable preoperative period in neonates with critical congenital heart disease
  • New insights into the effect of patent ductus arteriosus device closure in premature infants